Around 50% of people wearing face masks are at risk for dermatoses, and the risk increases with the length of time the mask is worn, researchers in Singapore suggest.
Abrocitinib shows consistent efficacy and safety in patients with moderate-to-severe atopic dermatitis, whether or not they ve already been treated with a biologic, researchers report.